Cargando…

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients

BACKGROUND AND AIMS: Although COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody response...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shiheng, Wang, Xiaolin, Feng, Mingyang, Liu, Xiaoman, Fan, Xinxing, Ran, Xiangui, Wang, Baogui, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944390/
https://www.ncbi.nlm.nih.gov/pubmed/36844234
http://dx.doi.org/10.3389/fmed.2023.1078666
_version_ 1784891904849084416
author Wu, Shiheng
Wang, Xiaolin
Feng, Mingyang
Liu, Xiaoman
Fan, Xinxing
Ran, Xiangui
Wang, Baogui
Wang, Hui
author_facet Wu, Shiheng
Wang, Xiaolin
Feng, Mingyang
Liu, Xiaoman
Fan, Xinxing
Ran, Xiangui
Wang, Baogui
Wang, Hui
author_sort Wu, Shiheng
collection PubMed
description BACKGROUND AND AIMS: Although COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses following COVID-19 vaccination among CHB patients. METHODS: Patients with CHB were included. All patients were vaccinated with two doses of inactivated vaccine (CoronaVac) or three doses of adjuvanted protein subunit vaccine (ZF2001). The adverse events were recorded and neutralizing antibody (NAb) were determined 14 days following the whole-course vaccination. RESULTS: A total of 200 patients with CHB were included. Specific NAb against SARS-CoV-2 were positive in 170 (84.6%) patients. The median (IQR) concentrations of NAb were 16.32 (8.44–34.10) AU/ml. Comparison of immune responses between CoronaVac and ZF2001 vaccines showed no significant differences in neither the concentrations of NAb nor the seropositive rates (84.4 vs. 85.7%). Moreover, we observed lower immunogenicity in older patients and in patients with cirrhosis or underlying comorbidities. The incidences of adverse events were 37 (18.5%) with the most common adverse event as injection side pain [25 (12.5%)], followed by fatigue [15 (7.5%)]. There were no differences in the frequencies of adverse between CoronaVac and ZF2001 (19.3% vs. 17.6%). Almost all of the adverse reactions were mild and self-resolved within a few days after vaccination. Severe adverse events were not observed. CONCLUSIONS: COVID-19 vaccines, CoronaVac and ZF2001 had a favorable safety profile and induced efficient immune response in patients with CHB.
format Online
Article
Text
id pubmed-9944390
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99443902023-02-23 Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients Wu, Shiheng Wang, Xiaolin Feng, Mingyang Liu, Xiaoman Fan, Xinxing Ran, Xiangui Wang, Baogui Wang, Hui Front Med (Lausanne) Medicine BACKGROUND AND AIMS: Although COVID-19 vaccination is recommended for the patients with chronic liver disease, the clinical outcomes of COVID-19 vaccinated in patients with chronic hepatitis B (CHB) has not been well characterized. The study aimed to explore the safety and specific antibody responses following COVID-19 vaccination among CHB patients. METHODS: Patients with CHB were included. All patients were vaccinated with two doses of inactivated vaccine (CoronaVac) or three doses of adjuvanted protein subunit vaccine (ZF2001). The adverse events were recorded and neutralizing antibody (NAb) were determined 14 days following the whole-course vaccination. RESULTS: A total of 200 patients with CHB were included. Specific NAb against SARS-CoV-2 were positive in 170 (84.6%) patients. The median (IQR) concentrations of NAb were 16.32 (8.44–34.10) AU/ml. Comparison of immune responses between CoronaVac and ZF2001 vaccines showed no significant differences in neither the concentrations of NAb nor the seropositive rates (84.4 vs. 85.7%). Moreover, we observed lower immunogenicity in older patients and in patients with cirrhosis or underlying comorbidities. The incidences of adverse events were 37 (18.5%) with the most common adverse event as injection side pain [25 (12.5%)], followed by fatigue [15 (7.5%)]. There were no differences in the frequencies of adverse between CoronaVac and ZF2001 (19.3% vs. 17.6%). Almost all of the adverse reactions were mild and self-resolved within a few days after vaccination. Severe adverse events were not observed. CONCLUSIONS: COVID-19 vaccines, CoronaVac and ZF2001 had a favorable safety profile and induced efficient immune response in patients with CHB. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9944390/ /pubmed/36844234 http://dx.doi.org/10.3389/fmed.2023.1078666 Text en Copyright © 2023 Wu, Wang, Feng, Liu, Fan, Ran, Wang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wu, Shiheng
Wang, Xiaolin
Feng, Mingyang
Liu, Xiaoman
Fan, Xinxing
Ran, Xiangui
Wang, Baogui
Wang, Hui
Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title_full Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title_fullStr Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title_full_unstemmed Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title_short Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients
title_sort safety and immunogenicity of inactivated covid-19 vaccine coronavac and the rbd-dimer–based covid-19 vaccine zf2001 in chronic hepatitis b patients
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944390/
https://www.ncbi.nlm.nih.gov/pubmed/36844234
http://dx.doi.org/10.3389/fmed.2023.1078666
work_keys_str_mv AT wushiheng safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT wangxiaolin safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT fengmingyang safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT liuxiaoman safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT fanxinxing safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT ranxiangui safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT wangbaogui safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients
AT wanghui safetyandimmunogenicityofinactivatedcovid19vaccinecoronavacandtherbddimerbasedcovid19vaccinezf2001inchronichepatitisbpatients